3-Dec-2024
No headlines found.
Artificial Intelligence (AI) Reshaping Healthcare Industry with Unimaginable Potential
Globe Newswire (Wed, 20-Nov 8:45 AM ET)
Business Wire (Tue, 12-Nov 9:26 AM ET)
Globe Newswire (Wed, 6-Nov 4:05 PM ET)
Clover Health to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 29-Oct 4:05 PM ET)
Clover Health to Report Third Quarter 2024 Financial Results on November 6
Globe Newswire (Wed, 23-Oct 4:05 PM ET)
2025 Clover Health Medicare Advantage Benefits Demonstrate Commitment to New Jersey Seniors
Globe Newswire (Tue, 15-Oct 9:15 AM ET)
Clover Health PPO Medicare Advantage Plans Earn 4 Star Rating for 2025
Globe Newswire (Thu, 10-Oct 5:03 PM ET)
Counterpart Health Names David Tsay M.D., Ph.D as Chief Medical Officer
Globe Newswire (Tue, 8-Oct 6:15 AM ET)
Globe Newswire (Thu, 26-Sep 4:00 PM ET)
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. Operating in two segments, Insurance and Non-Insurance, Clover Health offers PPO and HMO plans to Medicare Advantage members in multiple states through its Insurance segment. In the Non-Insurance segment, the company participates in the ACO REACH Model. The majority of revenue is generated from the insurance segment, reflecting the significance of its healthcare insurance offerings.
Clover Health Investments Corp. - Class A trades on the NASDAQ stock market under the symbol CLOV.
As of December 3, 2024, CLOV stock price declined to $3.40 with 3,263,766 million shares trading.
CLOV has a beta of 1.81, meaning it tends to be more sensitive to market movements. CLOV has a correlation of 0.07 to the broad based SPY ETF.
CLOV has a market cap of $1.70 billion. This is considered a Small Cap stock.
Last quarter Clover Health Investments Corp. - Class A reported $331 million in Revenue and -$.02 earnings per share. This fell short of revenue expectation by $-15 million and exceeded earnings estimates by $.02.
In the last 3 years, CLOV traded as high as $4.80 and as low as $.61.
The top ETF exchange traded funds that CLOV belongs to (by Net Assets): VTI, VXF, SCHA, VHT, PRFZ.
CLOV has outperformed the market in the last year with a price return of +257.9% while the SPY ETF gained +33.1%. CLOV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +36.0% and +3.7%, respectively, while the SPY returned +9.7% and +2.3%, respectively.
CLOV support price is $3.32 and resistance is $3.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLOV shares will trade within this expected range on the day.